uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Onkologisk endokrinologi)
2012 (English)In: Clinical Oncology, ISSN 0936-6555, E-ISSN 1433-2981, Vol. 24, no 4, 282-293 p.Article in journal (Refereed) Published
Abstract [en]

Neuroendocrine tumours (NETS) are a genetically diverse group of malignancies that sometimes produce peptides causing characteristic hormonal syndromes. NETs can be clinically symptomatic (functioning) or silent (non-functioning); both types frequently synthesise more than one peptide, although often these are not associated with specific syndromes. Based on data from various sources, the incidence and prevalence of NETs is increasing. The primary treatment goal for patients with NETs is curative, with symptom control and the limitation of tumour progression as secondary goals. Surgery is the only possible curative approach and so represents the traditional first-line therapy. However, as most patients with NETs are diagnosed once metastases have occurred, curative surgery is generally not possible. Patients therefore require chronic postoperative medical management with the aim of relieving symptoms and, in recent years, suppressing tumour growth and spread. Somatostatin analogues, such as octreotide long-acting repeatable (LAR), can improve the symptoms of carcinoid syndrome and stabilise tumour growth in many patients. Results from the PROMID study show that octreotide LAR 30 mg is an effective antiproliferative treatment in patients with newly diagnosed, functionally active or inactive, well-differentiated metastatic midgut NETs. An antiproliferative effect can also be achieved with everolimus, and combination therapy with octreotide LAR has shown synergistic antiproliferative activity. In the future, pasireotide, the multi-receptor targeted somatostatin analogue, has the potential to be an effective therapy for de novo or octreotide-refractory carcinoid syndrome and for inhibiting tumour cell proliferation. Peptide receptor radiotherapy with [90]yttrium-DOTATOC or [177]lutetium-DOTATE is also a new interesting treatment option for NETs.

Place, publisher, year, edition, pages
2012. Vol. 24, no 4, 282-293 p.
Keyword [en]
CgA, neuroendocrine tumours, octreotide, PRRT, somatostatin analogues, TNM staging
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-174351DOI: 10.1016/j.clon.2011.08.006ISI: 000302987300005OAI: oai:DiVA.org:uu-174351DiVA: diva2:528228
Available from: 2012-05-24 Created: 2012-05-15 Last updated: 2012-05-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Öberg, Kjell E
By organisation
Department of Medical Sciences
In the same journal
Clinical Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 169 hits
ReferencesLink to record
Permanent link

Direct link